tradingkey.logo

Sensus Healthcare Inc

SRTS
View Detailed Chart
5.040USD
+0.200+4.13%
Close 02/06, 16:00ETQuotes delayed by 15 min
82.86MMarket Cap
LossP/E TTM

Sensus Healthcare Inc

5.040
+0.200+4.13%
Intraday
1m
30m
1h
D
W
M
D

Today

+4.13%

5 Days

-1.75%

1 Month

+13.00%

6 Months

-5.44%

Year to Date

+26.63%

1 Year

-17.11%

View Detailed Chart

Key Insights

Sensus Healthcare Inc's fundamentals are relatively very healthy, with an industry-leading ESG disclosure.and its growth potential is significant.Its valuation is considered fairly valued, ranking 75 out of 205 in the Healthcare Equipment & Supplies industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 7.33.In the medium term, the stock price is expected to trend up.The company has been performing well in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Sensus Healthcare Inc's Score

Industry at a Glance

Industry Ranking
75 / 205
Overall Ranking
207 / 4521
Industry
Healthcare Equipment & Supplies

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score
Previous score

Media Coverage

Last 24 hours
Coverage Level

Very Low
Very High
Negative

Sensus Healthcare Inc Highlights

StrengthsRisks
Sensus Healthcare, Inc. is a medical device company that is engaged in the development and delivery of non-invasive treatments for skin cancer and keloids. The Company, leveraging its superficial radiotherapy (SRT and IG-SRT) technology, provides healthcare providers with a patient-centric treatment platform. Its products and services include SRT-100, SRT-100 Vision, SRT-100+, Sentinel service program and others. The SRT-100 is a photon x-ray low energy SRT system that provides patients an alternative to surgery for treating non-melanoma skin cancers, including basal cell and squamous cell skin cancers and other skin conditions such as keloids. The SRT-100 Vision provides customers with additional options compared to the SRT-100 base model. These additional options allow for dedicated treatment planning and full treatment progression documentation in a patient’s record. The SRT-100+ offers all the same features as the SRT-100, with the addition of remote diagnostics and other features.
Growing
The company is in a growing phase, with the latest annual income totaling USD 41.81M.
Undervalued
The company’s latest PE is -27.37, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 4.96M shares, decreasing 25.49% quarter-over-quarter.
Held by James Simons
Star Investor James Simons holds 261.13K shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of -0.03.

Analyst Rating

Based on 3 analysts
Buy
Current Rating
7.333
Target Price
+51.52%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Sensus Healthcare Inc News

More news coming soon, stay tuned...

Financial Indicators

EPS

Relevant data have not been disclosed by the company yet.

Total revenue

Relevant data have not been disclosed by the company yet.

Sensus Healthcare Inc Info

Sensus Healthcare, Inc. is a medical device company that is engaged in the development and delivery of non-invasive treatments for skin cancer and keloids. The Company, leveraging its superficial radiotherapy (SRT and IG-SRT) technology, provides healthcare providers with a patient-centric treatment platform. Its products and services include SRT-100, SRT-100 Vision, SRT-100+, Sentinel service program and others. The SRT-100 is a photon x-ray low energy SRT system that provides patients an alternative to surgery for treating non-melanoma skin cancers, including basal cell and squamous cell skin cancers and other skin conditions such as keloids. The SRT-100 Vision provides customers with additional options compared to the SRT-100 base model. These additional options allow for dedicated treatment planning and full treatment progression documentation in a patient’s record. The SRT-100+ offers all the same features as the SRT-100, with the addition of remote diagnostics and other features.
Ticker SymbolSRTS
CompanySensus Healthcare Inc
CEOSardano (Joseph C)
Websitehttps://sensushealthcare.com/
KeyAI